Conditions

Hyperparathyroidism

  • Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-­Refractory DTC

  • Maximal Tolerated Dose I­-131 Therapy for Advanced Thyroid Cancer and Determination of Iodine Refractory Disease